501c3 dedicated to discovering treatments for ME/CFS, LongCovid and IACCs, collaborating with expert clinicians and scientists.https://bsky.app/profile/simmaronresearch.bsky.socialhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mw2bepo6322kWe are proud to announce that we have achieved an R-01 grant from NIH. This prestigious award is a huge feat for ME research and highlights the work that Simmaron has been doing to uncover mechanistic drivers in #ME and #LongCovid that can lead to treatment options for patients. Congrats team!21 Sep 2026 17:46 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mw2bepo6322khttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mvyeux4u4c2gOur rapamycin studies are very promising, yet we know the findings need to be confirmed in a placebo-controlled trial. Listen to Dr. Gunnar Gottschalk explain why we studied mechanisms of rapamycin in responders, and how a random controlled trial can cut through heterogeneity in #ME. #PEM #Longcovid20 Sep 2026 23:44 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mvyeux4u4c2ghttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mvdw7cphus2gThe recently published findings from Phase II of our rapamycin treatment trial describe 3 pathways that are disrupted in #ME patients and are improved through treatment with Rapamycin. We summarize those findings in a series of updates, starting with mitochondrial dysfunction. bit.ly/4xhafmi12 Sep 2026 20:28 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mvdw7cphus2ghttps://bsky.app/profile/simmaronresearch.bsky.social/post/3muzdctm4p22gInterested in finding out more about our #ME and #LongCovid research and upcoming work? Sign up for email updates! www.simmaronresearch.com/signup #MECFS #POTS08 Sep 2026 15:23 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3muzdctm4p22ghttps://bsky.app/profile/simmaronresearch.bsky.social/post/3muagpdoj6s2hDr. Avik Roy summarizes our first scientific aim with Phase II of the rapamycin trial. Take a listen for yourself and find out why this trial is different from past endeavours.29 Aug 2026 17:47 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3muagpdoj6s2hhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3muaghdhtrc2hDoes Rapamycin improve mitochondrial energy metabolism in ME/CFS patients? Listen to Dr. Avik Roy explain the importance of mitochondrial energy and the impact found in the Rapamycin trial.29 Aug 2026 17:43 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3muaghdhtrc2hhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3msmhjn4bds2fOur decentralized #rapamycin trial allowed #SevereME patients to participate. When necessary, we reduced blood draw volumes and made every effort to help patients complete surveys. In a few cases, this meant conducting surveys over the phone. We all need new models. #ME #MECFS #Longcovid09 Aug 2026 01:44 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3msmhjn4bds2fhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mrdbn7xzfk2rA Simmaron short explaining how our #rapamycin observational trial is filling unmet needs in #MECFS treatment trials. @ggottschalk.bsky.social @avikroy.bsky.social @AgelessRX #POTS #Longcovid23 Jul 2026 16:39 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mrdbn7xzfk2rhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mqwxpycp622aHere's a short summary of our newest Jnl of Translational Medicine pub sharing results of Ph 2 of our rapamycin trial & showing how rapamycin may tie three converging threads of metabolic impairment together in #MECFS. #Longcovid #POTS simmaronresearch.salsalabs.org/jtrrapaph2pub18 Jul 2026 19:10 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mqwxpycp622ahttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mqptb3m5js2dRapamycin may tie three converging threads of metabolic impairment together in #MECFS. Here's a replay of Simmaron's team detailing new findings from Ph 2 of our rapamycin trial, in case you missed it! TY Solve for hosting us! #LongCovid #POTS https://www.youtube.com/watch?v=oJnUW-B089I15 Jul 2026 23:01 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mqptb3m5js2dhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mqmzgyu5ok2x2 hours to go! Register and hear our team detail findings published yesterday in Journal of Translational Medicine on Ph II of our rapamycin trial. [contains quote post or other embedded content]14 Jul 2026 20:14 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mqmzgyu5ok2xhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mqkp7elcyc2fWe're excited to announce Journal of Translation Medicine published findings from Phase II of our clinical trial evaluating low-dose rapamycin in people with #MECFS. This work builds upon years of laboratory research into mTOR signaling, autophagy, and mitochondrial dysfunction. 🧵13 Jul 2026 22:05 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mqkp7elcyc2fhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mpqyj4adu22n@solveme.bsky.social Our Simmaron science team has upcoming news you want to hear! Sign up for updates, and help keep us out of your spam folder. #ME #MECFS #LongCovid #PEM www.simmaronresearch.com/signup03 Jul 2026 16:43 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mpqyj4adu22nhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mp2zxdpyzc2mWhat if a single gene involved in cellular recycling could help explain symptoms of #MECFS and #LongCOVID? Our findings published in Inflammation Research this Spring dig into that question. This study focused on ATG13, a key regulator of autophagy, which we found increased in a subset of patients.24 Jun 2026 23:10 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mp2zxdpyzc2mhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mjzmiam74c2vWhy placebo trials for #MECFS & #LongCovid? It’s how drugs get approved, and we have none. Placebo trials change medicine. We'll compare RAPAMYCIN with placebo, and all will receive treatment. We seek to prove which subset responds and change medicine, finally. www.simmaronresearch.com/donate21 Apr 2026 18:30 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mjzmiam74c2vhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mioltu3zvk25#ME & #LongCovid have no FDA approval, no successful placebo-controlled trial, no accepted biomarker. Our placebo-controlled rapamycin trial is a strategic opportunity for change. Read how testing biomarkers with treatment holds so much promise: simmaronresearch.salsalabs.org/placebotrial #MECFS04 Apr 2026 15:54 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mioltu3zvk25https://bsky.app/profile/simmaronresearch.bsky.social/post/3mijw7emsnk2jWhy low-dose rapamycin? It regulates mTOR & autophagy, pathways that may be disrupted in #MECFS & #LongCOVID. Our placebo-controlled trial measures biomarkers, immune signaling, and metabolics to learn why some improve, and who is likely to. Help us prove it. DONATE: www.simmaronresearch.com/donate02 Apr 2026 19:16 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mijw7emsnk2jhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mi7sktkups2lOur placebo-controlled trial will pay for the costs of rapamycin, placebo, safety tests, biomarker tests and clinical work, to ease patient burden & so results aren’t influenced by costs. A generous donor will double your gift! Help prove treatments for #ME #LongCovid www.simmaronresearch.com/donate29 Mar 2026 18:44 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mi7sktkups2lhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mhvnw6yuok2p1️⃣ #MECFS and #LongCOVID affect millions worldwide — yet no @FDA approved treatment exists. 2️⃣ Our team at Simmaron Research is studying low-dose rapamycin, a drug that regulates cellular pathways involved in inflammation and autophagy. Thread 🧵1/425 Mar 2026 17:55 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mhvnw6yuok2phttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mho5so4etk2zOur new placebo-controlled rapamycin trial is based on 4 publications of our work on mechanisms & biomarkers disrupting autophagy in a subset of #MECFS & #Longcovid. Phase 1 of our treatment & biomarker trial was published in Jnl of Translational Medicine: https://link.springer.com/article/10.1186/s12967-025-07213-8. 1/4🧵22 Mar 2026 18:18 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mho5so4etk2zhttps://bsky.app/profile/simmaronresearch.bsky.social/post/3mhliy564qc2mWe’re launching a placebo-controlled study of rapamycin for #MECFS and #LongCOVID. Early data from our Phase II trial shows promise — now we must test it under rigorous blinded conditions. Help us make it happen. Donate to support the study. www.simmaronresearch.com/donate #ME #Rapamycin21 Mar 2026 17:00 +0000at://did:plc:owgckusp4fxmf3mybklma32f/app.bsky.feed.post/3mhliy564qc2m